Pleconaril
- Generic Name
- Pleconaril
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H18F3N3O3
- CAS Number
- 153168-05-9
- Unique Ingredient Identifier
- 9H4570Q89D
- Background
Pleconaril is an antiviral drug from viral capsid inhibitor class, manufactured by Schering-Plough and intended for the prevention of acute asthma exacerbations and common cold symptoms in asthmatic patients who have had exposure to picornavirus. It acts by inhibiting viral replication. The use of pleconaril has not gained approval by the U.S. Food and Drug Administration (FDA) due to the fact that it has been found to induce CYP3A enzyme activity, therefore increasing the risk for serious drug interactions.
- Indication
Investigated for use/treatment in upper respiratory infection.
- Associated Conditions
- -
- Associated Therapies
- -
Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295)
- Conditions
- RhinovirusAsthmaCommon ColdPicornavirus Infection
- Interventions
- Drug: Placebo to PleconarilDrug: Pleconaril
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 311
- Registration Number
- NCT00394914
Pleconaril Enteroviral Sepsis Syndrome
- First Posted Date
- 2002-03-07
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Target Recruit Count
- 61
- Registration Number
- NCT00031512
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center - Pediatrics, Dallas, Texas, United States
🇺🇸University of Texas Medical Branch - Pediatrics - Infectious Diseases and Immunology - Galveston, Galveston, Texas, United States
🇺🇸The University of Chicago - Comer Children's Hospital - Infectious Diseases, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.